TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Unicycive Therapeutics ( (UNCY) ) has provided an update.
On August 15, 2025, Unicycive Therapeutics was named in a securities class action lawsuit filed in the Northern District of California. The lawsuit alleges violations of federal securities laws related to the company’s public statements about its new drug application for oxylanthanum carbonate. Unicycive believes the claims are without merit and plans to defend itself vigorously.
The most recent analyst rating on (UNCY) stock is a Buy with a $30.00 price target. To see the full list of analyst forecasts on Unicycive Therapeutics stock, see the UNCY Stock Forecast page.
Spark’s Take on UNCY Stock
According to Spark, TipRanks’ AI Analyst, UNCY is a Underperform.
Unicycive Therapeutics has significant financial challenges, including ongoing net losses and a reliance on debt for financing, which weigh heavily on its stock score. The technical analysis reveals a bearish trend, as the stock is trading below major moving averages. Valuation metrics further dampen the attractiveness of the stock due to negative profitability indicators. Without earnings call insights or recent corporate events to improve prospects, the overall score reflects these financial and technical weaknesses.
To see Spark’s full report on UNCY stock, click here.
More about Unicycive Therapeutics
Unicycive Therapeutics, Inc. operates in the pharmaceutical industry, focusing on developing treatments for kidney diseases. Its primary product includes oxylanthanum carbonate, a phosphate binder for treating hyperphosphatemia in chronic kidney disease patients on dialysis.
Average Trading Volume: 754,102
Technical Sentiment Signal: Sell
Current Market Cap: $83.01M
See more data about UNCY stock on TipRanks’ Stock Analysis page.